Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 22.7% year on year to $177.8 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.49 per share was 2.8% above analysts’ consensus estimates.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 11.7%. This drawdown was worse than the S&P 500’s 5.2% decline.
Collegium Pharmaceutical’s stock price has taken a beating over the past six months, shedding 31.6% of its value and falling to $26.01 per share. This might have investors contemplating their next move.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical (NASDAQ:COLL) and the rest of the branded pharmaceuticals stocks fared in Q4.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX) and the rest of the branded pharmaceuticals stocks fared in Q4.
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.5% year on year to $181.9 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.77 per share was 15.1% above analysts’ consensus estimates.
COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
